Does Smoking Increase Fatty Liver Risk?

Does smoking increase fatty liver risk? Evidence consistently shows that cigarette smoking is an independent risk factor for metabolic dysfunction-associated steatotic liver disease (MASLD), previously known as non-alcoholic fatty liver disease (NAFLD). Tobacco compounds drive oxidative stress, impair insulin sensitivity and promote dyslipidaemia, all of which encourage fat accumulation in the liver. Understanding how smoking affects liver health, alongside other modifiable risk factors such as diet, alcohol and physical inactivity, is essential for anyone looking to protect their long-term liver health.

Does smoking increase your risk of developing fatty liver disease?

Yes, smoking is an independent risk factor for MASLD, promoting liver fat accumulation through oxidative stress, impaired insulin sensitivity and dyslipidaemia, even after accounting for obesity and alcohol use.

Yes, smoking is associated with an increased risk of developing fatty liver disease, including metabolic dysfunction-associated steatotic liver disease (MASLD). MASLD was previously known as non-alcoholic fatty liver disease (NAFLD), and many UK and NHS resources still use the older term, so the two names refer to the same condition. Research, including systematic reviews and meta-analyses that have adjusted for confounding variables such as obesity and alcohol use, has consistently identified cigarette smoking as an independent risk factor for liver fat accumulation and for the progression of liver disease to more serious stages, including fibrosis and cirrhosis.

The mechanisms by which smoking harms the liver are several. Tobacco smoke contains thousands of toxic compounds, including reactive oxygen species that promote oxidative stress within liver cells. This oxidative stress triggers inflammation and can accelerate hepatocyte injury. Smoking also impairs insulin sensitivity, which is a key driver of fat accumulation in the liver, and it promotes dyslipidaemia, raising triglyceride levels and reducing protective high-density lipoprotein (HDL) cholesterol.^[6][4] Together, these effects create conditions that favour the development and worsening of liver steatosis. These mechanisms are described in the European Association for the Study of the Liver (EASL) clinical practice guidelines on MASLD.

Many people who smoke also have other risk factors, such as obesity, type 2 diabetes or excessive alcohol consumption, which independently contribute to liver disease. However, studies that have adjusted for these confounding variables still find a meaningful association between smoking and liver fat, suggesting that tobacco use has a direct, harmful effect on liver health beyond its indirect metabolic consequences.

For anyone concerned about their liver health, understanding all modifiable risk factors, including smoking, is an important first step in reducing long-term harm.

Can stopping smoking help improve a fatty liver?

Stopping smoking can reduce oxidative stress and liver inflammation, potentially improving liver fat and enzyme levels, particularly in those without advanced fibrosis, when combined with other lifestyle changes.

Stopping smoking is likely to benefit liver health, and there is evidence to suggest that smoking cessation can contribute to improvements in liver fat and inflammation over time, particularly in people who have not yet developed significant scarring (fibrosis). While the liver has a remarkable capacity for recovery when harmful exposures are removed, the extent of improvement depends on the stage of disease at the point of stopping and on whether other risk factors are also addressed.

After stopping smoking, the body begins to reduce its burden of oxidative stress relatively quickly. Insulin sensitivity can improve, and the inflammatory processes that tobacco compounds drive within the liver may begin to settle. For people in the earlier stages of fatty liver disease, these changes may translate into measurable reductions in liver fat on imaging and improvements in liver enzyme levels on blood tests.

NICE guidance on tobacco prevention and cessation (NG209) recommends a combination of behavioural support and pharmacotherapy for people who wish to stop smoking.^[1] Options that may be available include:

• Nicotine replacement therapy (NRT), available in various forms including patches, gum and lozenges

• Varenicline (Champix), a prescription medicine; availability in the UK has varied and your GP or Stop Smoking Service can advise on current access^[8][9]

• Bupropion, a prescription medicine used as a second-line option

• Nicotine-containing e-cigarettes, which NICE recognises as an option to support quitting for people who choose to use them^[11][12]

Important safety note: varenicline and bupropion are generally not recommended during pregnancy or breastfeeding.^[7][8] If you are pregnant or breastfeeding and wish to stop smoking, speak to your GP or midwife, as NRT may be considered with appropriate support and supervision.

NHS Stop Smoking Services provide structured support and have been shown to significantly improve quit rates compared with willpower alone. You can self-refer to local services or ask your GP for a referral. Your GP can also prescribe appropriate treatments.

Stopping smoking alone is unlikely to resolve fatty liver disease if other contributing factors, such as excess body weight, poor diet or physical inactivity, remain unaddressed. Smoking cessation is best understood as one important component of a broader lifestyle approach to liver health.

What other lifestyle factors make fatty liver worse?

Excess body weight, alcohol consumption, a diet high in ultra-processed foods and refined sugars, physical inactivity, type 2 diabetes and obstructive sleep apnoea all independently worsen fatty liver disease.

Excess body weight is one of the most significant lifestyle factors that worsens fatty liver disease, particularly when fat is carried around the abdomen. Obesity drives insulin resistance, which causes the liver to accumulate fat and promotes the progression from simple steatosis to the more serious metabolic dysfunction-associated steatohepatitis (MASH), previously called non-alcoholic steatohepatitis (NASH). Clinical studies, including those referenced in NICE guideline NG49 (Non-alcoholic fatty liver disease: assessment and management) and EASL guidelines, have shown that even modest weight loss of around 5 per cent of body weight can reduce liver fat and inflammation, with greater reductions (generally 7 to 10 per cent or more) associated with improvements in fibrosis in those with more advanced disease.^[2][13]

Alcohol consumption is another major contributor. Even in people who do not meet the clinical definition of alcohol-related liver disease, regular drinking can worsen liver fat, increase inflammation and accelerate fibrosis. The UK Chief Medical Officers' low-risk drinking guidelines, reflected on NHS alcohol advice pages, recommend drinking no more than 14 units per week, spread across at least three days, with several drink-free days.^[14] Many hepatologists advise complete abstinence in those with more advanced disease.

Dietary patterns also play a central role. Diets high in ultra-processed foods, refined carbohydrates, added sugars (particularly fructose) and saturated fats are strongly linked to liver fat accumulation. Conversely, a Mediterranean-style diet, rich in vegetables, wholegrains, legumes, fish and olive oil, has evidence supporting its benefit for liver health, as noted in EASL guidelines.^[3][15] Physical inactivity compounds these dietary risks by reducing the body's ability to metabolise fat and by worsening insulin resistance.

Other factors that may worsen fatty liver include:

• Type 2 diabetes and pre-diabetes, which are closely linked to liver fat through shared metabolic pathways

• Certain medicines, such as corticosteroids, tamoxifen and some antipsychotics, which can promote hepatic steatosis; do not stop any prescribed medicine without first speaking to your doctor

• Obstructive sleep apnoea (OSA), which causes intermittent hypoxia and has been independently associated with liver inflammation; if OSA is suspected, assessment and treatment may also benefit liver health^[18][19]

Addressing these factors together, rather than in isolation, gives the best chance of halting or reversing liver disease progression.

When should you see a GP about fatty liver symptoms?

See your GP if you have persistent fatigue, right upper abdominal discomfort, unexplained weight loss or nausea, especially with known liver risk factors; seek emergency care for jaundice, vomiting blood or black stools.

You should see your GP if you experience persistent symptoms that may suggest liver disease, particularly if you have known risk factors such as obesity, type 2 diabetes, heavy alcohol use or a history of smoking. Fatty liver disease is often silent in its early stages and is frequently discovered incidentally on an ultrasound scan or through abnormal liver enzyme results on a routine blood test. However, as the disease progresses, symptoms can develop and should not be ignored.

Symptoms that warrant a GP appointment include:

• Persistent fatigue that is unexplained and does not improve with rest

• Discomfort or a dull ache in the upper right side of the abdomen, where the liver sits

• Unexplained weight loss or loss of appetite

• Nausea that is ongoing without an obvious cause

If you develop signs that may indicate more advanced liver disease or cirrhosis, contact your GP promptly. These include yellowing of the skin or whites of the eyes (jaundice), swelling of the abdomen, confusion or difficulty concentrating, or easy bruising and bleeding.

Call 999 or go to your nearest A&E immediately if you vomit blood, notice blood in your stools, or pass black and tarry stools, as these may indicate serious bleeding from the digestive tract. If jaundice appears suddenly or is accompanied by severe abdominal pain and fever, contact NHS 111 for urgent advice.

Your GP can arrange blood tests to assess liver function and check for related metabolic conditions, as well as an abdominal ultrasound. In line with NICE guideline NG49, GPs may also use non-invasive fibrosis scoring tools such as the FIB-4 score or the NAFLD Fibrosis Score as a first step in assessing the risk of significant liver scarring. Ultrasound alone is not sufficient to rule out fibrosis. Where the initial score suggests intermediate or higher risk, further assessment with an Enhanced Liver Fibrosis (ELF) test or referral to a hepatologist or gastroenterologist may follow. If you believe a medicine you are taking may be contributing to your liver symptoms, discuss this with your GP or prescriber before making any changes. Suspected adverse drug reactions can also be reported to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk. Early detection and management of fatty liver disease significantly improves long-term outcomes, so do not delay seeking advice if you are concerned.

Scientific References

1. Tobacco: preventing uptake, promoting quitting and treating dependence (NG209).
2. Metabolic dysfunction-associated steatotic liver disease (formerly NAFLD): assessment and management (NG49).
3. EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease.
4. The relationship between tobacco and non-alcoholic fatty liver disease incidence: a systematic review and meta-analysis of observational studies.
5. Understanding molecular mechanisms driving cadmium-induced mitochondrial dysfunction in human metabolic liver disease.
6. Cigarette smoking and alcohol-related liver disease.
7. Varenicline: pregnancy, breastfeeding and fertility.
8. Varenicline 1 mg film-coated tablets – Summary of Product Characteristics.
9. Champix – supply shortage information.
10. Quit smoking with nicotine-free medicines – Better Health.
11. Smoking cessation interventions and services – Evidence review C: advice on e-cigarettes (NG209 supporting evidence).
12. Using e-cigarettes to stop smoking.
13. Non-alcoholic fatty liver disease (NAFLD).
14. Alcohol consumption: advice on low risk drinking – UK Chief Medical Officers.
15. Impact of weight loss and reduction of ultra-processed foods on liver fat content in MASLD: a randomised controlled trial.
16. Very low energy ketogenic diet vs. Mediterranean diet for MASLD: superior steatosis reduction in a randomised pilot study.
17. A culturally adapted online Mediterranean diet intervention for MASLD (TIMA): study protocol for a randomised controlled trial.
18. Association between obstructive sleep apnoea and non-alcoholic fatty liver disease: a systematic review and meta-analysis.
19. Obstructive sleep apnoea is associated with fatty liver and abnormal liver enzymes: a meta-analysis.

Frequently Asked Questions